Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 201–300 of 1,001
The hallmarks of CAFs in cancer invasion
Atieh, Y., & Vignjevic, D. M. (2016) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2016.07.004 · Cited by 128
“Upon activation, PDGFR dimerizes and activates multiple downstream pathways such as the phosphatidylinositol 3-kinase (PI3K) pathway, which leads to increased actomyosin activity, and the Ras pathway that induces cell proliferation (Cully et al., 2006; Schubbert et al., 2007).”
BackgroundPI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy
Manfredi, G. I., Dicitore, A., Gaudenzi, G., Caraglia, M., Persani, L., & Vitale, G. (2014) · Endocrine · doi:10.1007/s12020-014-0380-1 · Cited by 110
“1) [8, 51, 52].”
Vecchione, L., Jacobs, B., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.021 · Cited by 119
Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
Wang, X.-S., Shankar, S., Dhanasekaran, S. M., Ateeq, B., Sasaki, A. T., Jing, X., Robinson, D., Cao, Q., Prensner, J. R., Yocum, A. K., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0022 · Cited by 112
See, W. L., Tan, I., Mukherjee, J., Nicolaides, T. P., & Pieper, R. O. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0334 · Cited by 108
UV-induced squamous cell carcinoma—a role for antiapoptotic signalling pathways
Rodust, P. M., Stockfleth, E., Ulrich, C., Leverkus, M., & Eberle, J. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09458.x · Cited by 105
Tumors of the neural crest: Common themes in development and cancer
Maguire, L. H., Thomas, A. R., & Goldstein, A. M. (2014) · Developmental Dynamics · doi:10.1002/dvdy.24226 · Cited by 119
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
Chung, E., & Kondo, M. (2010) · Immunologic Research · doi:10.1007/s12026-010-8187-5 · Cited by 114
Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN)
Su, Z.-Z., Lee, S., Emdad, L., Lebdeva, I. V., Gupta, P., Valerie, K. C., Sarkar, D., & Fisher, P. B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807975106 · Cited by 118
Rizzo, S., Bronte, G., Fanale, D., Corsini, L. R., Silvestris, N., Santini, D., Gulotta, G., Bazan, V., Gebbia, N., Fulfaro, F., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70021-9 · Cited by 177
MAPK pathway activation and the origins of pediatric low‐grade astrocytomas
Tatevossian, R., Lawson, A. R. J., Forshew, T., Hindley, G., Ellison, D. W., & Sheer, D. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21978 · Cited by 105
“A common mechanism of deregulating the MAPK pathway is the activation of RAS by specific point mutations which are believed to occur in 20–30% of human cancers (Downward, 2003; Schubbert et al., 2007).”
BackgroundA Restricted Spectrum of Mutations in the SMAD4 Tumor-Suppressor Gene Underlies Myhre Syndrome
Caputo, V., Cianetti, L., Niceta, M., Carta, C., Ciolfi, A., Bocchinfuso, G., Carrani, E., Dentici, M. L., Biamino, E., Belligni, E. F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.12.011 · Cited by 111
Melo-Cardenas, J., Xu, Y., Wei, J., Tan, C., Kong, S., Gao, B., Montauti, E., Kirsammer, G., Licht, J. D., Yu, J., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811760 · Cited by 84
Specific functions of lysosomal proteases in endocytic and autophagic pathways
Müller, S., Dennemärker, J., & Reinheckel, T. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.07.003 · Cited by 116
Liu, K., Rao, W., Parikh, H. I., Li, Q., Guo, T. L., Grant, S., Kellogg, G. E., & Zhang, S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.031 · Cited by 114
Current Insights of BRAF Inhibitors in Cancer
Agianian, B., & Gavathiotis, E. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01306 · Cited by 112
Guanine nucleotide exchange factors for RhoGTPases: Good therapeutic targets for cancer therapy?
Lazer, G., & Katzav, S. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.022 · Cited by 117
Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer
Kemper, K., Versloot, M., Cameron, K., Colak, S., de Sousa e Melo, F., de Jong, J. H., Bleackley, J., Vermeulen, L., Versteeg, R., Koster, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3066 · Cited by 101
H-Ras is degraded by Wnt/β-catenin signaling via β-TrCP-mediated polyubiquitylation
Kim, S., Yoon, J., Jeong, W.-J., Jeon, S.-H., Park, Y., Yoon, J., Park, Y. N., Kim, H., & Choi, K. (2009) · Journal of Cell Science · doi:10.1242/jcs.040493 · Cited by 103
Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation
Bunda, S., Heir, P., Srikumar, T., Cook, J. D., Burrell, K. E., Kano, Y., Lee, J. E., Zadeh, G. M., Raught, B., & Ohh, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406559111 · Cited by 113
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Sabnis, A. J., Cheung, L. S., Dail, M., Kang, H. C., Santaguida, M. A., Hermiston, M. L., Passegue, E. A., Shannon, K., & Braun, B. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000059 · Cited by 106
Self-citationZmajkovicova, K., Jesenberger, V., Catalanotti, F., Baumgärtner, C., Reyes, G. X., & Baccarini, M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.037 · Cited by 105
Biochemical and Functional Characterization of Germ Line KRAS Mutations
Schubbert, S., Bollag, G., Lyubynska, N., Nguyen, H., Kratz, C. P., Zenker, M., Niemeyer, C. M., Molven, A., & Shannon, K. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00965-07 · Cited by 99
Self-citationJin, X., Pan, Y., Wang, L., Ma, T., Zhang, L., Tang, A., Billadeau, D. D., Wu, H., & Huang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3143 · Cited by 98
Kunimoto, H., Meydan, C., Nazir, A., Whitfield, J. T., SHANK, K. R., Rapaport, F., Maher, R., Pronier, E., Meyer, S. C., Garrett-Bakelman, F. E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.012 · Cited by 107
Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Lo, H. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357970 · Cited by 102
Hafner, C. M., & Groesser, L. (2012) · Cell Cycle · doi:10.4161/cc.23108 · Cited by 98
Alternative modulation of protein–protein interactions by small molecules
Fischer, G., Rossmann, M., & Hyvönen, M. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.04.006 · Cited by 96
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
A polymorphism in a let‐7 microRNA binding site of KRAS in women with endometriosis
Grechukhina, O., Petracco, R., Popkhadze, S., Massasa, E., Paranjape, T., Chan, E., Flores, I., Weidhaas, J. B., & Taylor, H. S. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100200 · Cited by 96
K-Ras V14I recapitulates Noonan syndrome in mice
Hernández-Porras, I., Fabbiano, S., Schuhmacher, A. J., Aicher, A., Cañamero, M., Cámara, J. A., Cussó, L., Desco, M., Heeschen, C., Mulero, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418126111 · Cited by 96
Goriely, A., McGrath, J. J., Hultman, C. M., Wilkie, A. O. M., & Malaspina, D. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12101352 · Cited by 96
Biomarkers in precision therapy in colorectal cancer
Reimers, M. S., Zeestraten, E. C. M., Kuppen, P. J. K., Liefers, G., & van de Velde, C. J. �. (2013) · Gastroenterology report · doi:10.1093/gastro/got022 · Cited by 105
Grewal, S. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.12.005 · Cited by 107
Kindler, T., Cornejo, M., Scholl, C., Liu, J., Leeman, D. S., Haydu, J. E., Fröhling, S., Lee, B. H., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-147587 · Cited by 97
Jankú, F., Kaseb, A. O., Tsimberidou, A. M., Wolff, R. A., & Kurzrock, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1687 · Cited by 100
Miglietta, G., Cogoi, S., Marinello, J., Capranico, G., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00622 · Cited by 98
Oncogenic G12D mutation alters local conformations and dynamics of K-Ras
Vatansever, S., Erman, B., & Gumus, Z. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-48029-z · Cited by 96
Fang, Z., Marshall, C. B., Nishikawa, T., Gossert, A. D., Jansen, J. M., Jahnke, W., & Ikura, M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.07.009 · Cited by 86
FGFR- gene family alterations in low-grade neuroepithelial tumors
Bale, T. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00898-6 · Cited by 93
Small GTP-binding proteins and their regulators in cardiac hypertrophy
Lezoualc’h, F., Metrich, M., Hmitou, I., Duquesnes, N., & Morel, É. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.01.011 · Cited by 101
“H-Ras, K-Ras and N-Ras are the most common targets for dominant gain-of-function mutations in human cancer [17].”
BackgroundJorge, A. A. L., Malaquias, A. C., Arnhold, I. J. P., & Mendonca, B. B. (2009) · Hormone Research in Paediatrics · doi:10.1159/000201106 · Cited by 100
Jin, J., Song, M., Kim, Y., Park, J., & Kwak, J. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20654 · Cited by 100
Wang, C., Cigliano, A., Delogu, S., Armbruster, J., Dombrowski, F., Evert, M., Chen, X., & Calvisi, D. F. (2013) · Cell Cycle · doi:10.4161/cc.25099 · Cited by 96
Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding
McCarthy, M. J., Pagba, C. V., Prakash, P., Naji, A. K., van der Hoeven, D., Liang, H., Gupta, A. K., Zhou, Y., Cho, K.-J., Hancock, J. F., et al. (2019) · ACS Omega · doi:10.1021/acsomega.8b03308 · Cited by 90
The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation
Luo, M., Gong, C., Chen, C.-H., Hu, H., Huang, P., Zheng, M., Yao, Y., Wei, S., Wulf, G. M., Lieberman, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.002 · Cited by 95
Dysregulation of astrocyte extracellular signaling in Costello syndrome
Krencik, R., Hokanson, K. C., Narayan, A. R., Dvornik, J., Rooney, G. E., Rauen, K. A., Weiss, L. A., Rowitch, D. H., & Ullian, E. M. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5645 · Cited by 95
Okumura, T., Ericksen, R. E., Takaishi, S., Wang, S. S. W., Dubeykovskiy, Z., Shibata, W., Betz, K. S., Muthupalani, S., Rogers, A. B., Fox, J. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1506 · Cited by 95
Phoenix, T. N., & Temple, S. (2010) · Genes & Development · doi:10.1101/gad.1839510 · Cited by 103
The Distinct Conformational Dynamics of K-Ras and H-Ras A59G
Lukman, S., Grant, B. J., Gorfe, A. A., Grant, G. H., & McCammon, J. A. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000922 · Cited by 90
Oberst, M. D., Fuhrmann, S. R., Mulgrew, K. A., Amann, M., Cheng, L., Lutterbuese, P., Richman, L. K., Coats, S., Baeuerle, P. A., & Hammond, S. A. (2014) · mAbs · doi:10.4161/19420862.2014.975660 · Cited by 101
Yuen, H., Chan, K.-K., Grills, C., Murray, J. T., Platt-Higgins, A. M., Eldin, O. S., O'Byrne, K. J., Janne, P. A., Fennell, D. A., Johnston, P. G., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2035 · Cited by 89
RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation
Saha, M., Carriere, A., Cheerathodi, M., Zhang, X., Lavoie, G., Rush, A. J., Roux, P. P., & Ballif, B. A. (2012) · Biochemical Journal · doi:10.1042/bj20120938 · Cited by 105
Spurlock, G., Bennett, E., Chuzhanova, N. A., Thomas, N. S., Jim, H.-P., Side, L. E., Davies, S., Haan, E., Kerr, B. A., Huson, S., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.065474 · Cited by 88
KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
Wang, H. L., Lopategui, J. R., Amin, M. B., & Patterson, S. D. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181c6962f · Cited by 100
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Cutaneous melanoma in genetically modified animals
Larue, L., & Beermann, F. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00411.x · Cited by 107
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K., Chen, J., Horng, G., Bellovin, D. I., Giuriato, S., Wang, C. S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002125 · Cited by 87
Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis
Seif, A. E. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.04.005 · Cited by 99
Dentici, M. L., Sárközy, A., Pantaleoni, F., Carta, C., Lepri, F. R., Ferese, R., Cordeddu, V., Martinelli, S., Briuglia, S., Digilio, M. C., et al. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.256 · Cited by 85
Galan, J. A., Geraghty, K. M., Lavoie, G., Kanshin, E., Tcherkezian, J., Calabrese, V., Jeschke, G. R., Turk, B. E., Ballif, B. A., Blenis, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405601111 · Cited by 85
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Loriot, Y., Mordant, P., Deutsch, É., Olaussen, K. A., & Soria, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.106 · Cited by 93
Zheng, Y., Yang, W., Xia, Y., Hawke, D. H., Liu, D. X., & Lu, Z. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05547-11 · Cited by 85
DLC1: a significant GAP in the cancer genome
Lahoz, A., & Hall, A. (2008) · Genes & Development · doi:10.1101/gad.1691408 · Cited by 96
Yang, Q., Lang, C., Wu, Z., Dai, Y., He, S., Guo, W., Huang, S., Du, H., Ren, D., & Peng, X. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1374-x · Cited by 86
Dick, F. A. (2007) · Cell Division · doi:10.1186/1747-1028-2-26 · Cited by 79
Nakaguro, M., Urano, M., Ogawa, I., Hirai, H., Yamamoto, Y., Yamaguchi, H., Tanigawa, M., Matsubayashi, J., Hirano, H., Shibahara, J., et al. (2019) · Histopathology · doi:10.1111/his.13990 · Cited by 83
“BRAF V600E substitution is one of the most common molecular changes found in human cancer.(24) Among salivary gland tumours, recurrent BRAF mutations are limited to a small percentage (4– 7%) of cases of salivary duct carcinoma.”
BackgroundK-ras and Wnt Signaling Synergize to Accelerate Prostate Tumorigenesis in the Mouse
Pearson, H. B., Phesse, T. J., & Clarke, A. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2895 · Cited by 94
Murray, M. T., Hraiki, A., Bebawy, M., Pazderka, C., & Rawling, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.008 · Cited by 101
Baba, Y., Nosho, K., Shima, K., Meyerhardt, J. A., Chan, A. T., Engelman, J. A., Cantley, L. C., Loda, M. F., Giovannucci, E. L., Fuchs, C. S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605846 · Cited by 86
Lu, T., Huang, G., Lu, T., Wu, J.-B., Wu, C., Yang, T., Iizuka, A., & Chen, Y.-F. (2009) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.05.023 · Cited by 87
Porta, M. S., Crous‐Bou, M., Wark, P. A., Vineis, P., Real, F. X., Malats, N., & Kampman, E. (2009) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2009.07.003 · Cited by 86
“2% or less of human pancreatic intraductal adenocarcinomas [2,4], onlymutations”
BackgroundInfluentialLee, H.-W., Kyung, T., Yoo, J., Kim, T., Chung, C., Ryu, J. Y., Lee, H., Park, K., Lee, S., Jones, W. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms2507 · Cited by 88
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
Cerrato, A., Falco, V. D., & Santoro, M. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0024 · Cited by 95
Li, Z.-L., & Buck, M. (2017) · Structure · doi:10.1016/j.str.2017.02.007 · Cited by 81
A Fifth of the Protein World: Rossmann-like Proteins as an Evolutionarily Successful Structural unit
Medvedev, K. E., Kinch, L. N., Schaeffer, R. D., Pei, J., & Grishin, N. V. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.166788 · Cited by 89
“Ras is a GTP-binding protein that regulates cellular responses to different extracellular stimuli and is oncogenic; cancer cells often express mutant Ras proteins.(109) The nucleotide-binding domain of Ras proteins adopts a six-stranded b-sheet with antiparallel b3 (order 321456) flanked by five helices (Figure 12D) a…”
BackgroundInfluentialNovel therapeutic agents for osteosarcoma
O’Day, K., & Gorlick, R. G. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.7 · Cited by 89
Park, J., Kusminski, C. M., Chua, S. C., & Scherer, P. E. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100595 · Cited by 84
Iliopoulos, D., Rotem, A., & Struhl, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0425 · Cited by 82
Molecular pathways in pancreatic carcinogenesis
Macgregor‐Das, A. M., & Iacobuzio–Donahue, C. A. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23213 · Cited by 99
Xu, J., Hedberg, C., Dekker, F. J., Li, Q., Haigis, K. M., Hwang, E., Waldmann, H., & Shannon, K. (2011) · Blood · doi:10.1182/blood-2011-06-358960 · Cited by 83
Self-citationRahmani, M., Anderson, A., Habibi, J. R., Crabtree, T. R., Aust, M. M., Harada, H., Ferreira‐Gonzalez, A., Dent, P., & Grant, S. (2009) · Blood · doi:10.1182/blood-2008-09-177881 · Cited by 81
Blaj, C., Schmidt, E. M., Lamprecht, S., Hermeking, H., Jung, A., Kirchner, T., & Horst, D. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2821 · Cited by 84
Long non-coding RNAs in cancer invasion and metastasis
Shen, X.-H., Qi, P., & Du, X. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.75 · Cited by 80
Arias-Romero, L. E., & Chernoff, J. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.828037 · Cited by 79
Schrader, K. A., Nelson, T. N., Luca, A. D., Huntsman, D. D., & McGillivray, B. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2008.01100.x · Cited by 79
Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases
Tamburrino, A., Molinolo, A., Salerno, P., Chernock, R. D., Raffeld, M. A., Xi, L., Gutkind, J. S., Moley, J. F., Wells, S. A., & Santoro, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2700 · Cited by 80
Advances in Pancreatic Ductal Adenocarcinoma Treatment
Anderson, E. M., Thomassian, S., Gong, J., Hendifar, A. E., & Osipov, A. (2021) · Cancers · doi:10.3390/cancers13215510 · Cited by 88
“Furthermore, although the goal of PEGPH20 treatment is to disrupt the ECM in an effort to improve drug delivery, it is possible that ECM disruption may increase the cancer’s ability to metastasize, thereby leading to worse outcomes [137].”
BackgroundInfluentialCDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
Costa-Cabral, S., Brough, R., Konde, A., Aarts, M., Campbell, J., Marinari, E., Riffell, J. L., Bardelli, A., Torrance, C. J., Lord, C. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149099 · Cited by 82
Shen, S., Yue, H., Li, Y., Qin, J., Li, K., Liu, Y., & Wang, J. (2013) · Tumor Biology · doi:10.1007/s13277-013-1087-2 · Cited by 81
Sheridan, C., Brumatti, G., Elgendy, M., Brunet, M., & Martin, S. J. (2010) · Oncogene · doi:10.1038/onc.2010.380 · Cited by 83
How cells switch HIPK2 on and off
Sombroek, D., & Hofmann, T. G. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.154 · Cited by 87
Direct Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 76
Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer
Subramaniam, D., Kaushik, G., Dandawate, P. R., & Anant, S. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170127095832 · Cited by 86
Liu, S., Gao, G., Yan, D., Chen, X., Yao, X., Guo, S., Li, G., & Zhao, Y. (2017) · Cancer Medicine · doi:10.1002/cam4.1030 · Cited by 76
RetractedWang, H., Daouti, S., Li, W.-H., Wen, Y., Rizzo, C., Higgins, B., Packman, K., Rosen, N., Boylan, J. F., Heimbrook, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4351 · Cited by 76
de Gooijer, M. C., Zhang, P., Weijer, R., Buil, L. C. M., Beijnen, J. H., & van Tellingen, O. (2017) · International Journal of Cancer · doi:10.1002/ijc.31052 · Cited by 81
Effect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth
Ahmed, A. U., Schmidt, R. L., Park, C. H., Reed, N. R., Hesse, S. E., Thomas, C. F., Molina, J. R., Deschamps, C. C., Yang, P., Aubry, M. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn365 · Cited by 76
Aranda, S., Álvarez‐Fernández, M., Turró, S., Laguna, A., & de la Luna, S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00394-08 · Cited by 103
Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
Baselga, J. M., & Rosen, N. X. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3700 · Cited by 87
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.